摘要
腹水是肝硬化患者失代偿期最为常见的临床症状,并存在于顽固性腹水、低钠血症、肝肾综合征等并发症之中,病情复杂,危害严重。内脏血管扩张是肝硬化腹水相关并发症的关键病理环节,针对该环节治疗有助于消除腹水症状,防止失代偿期肝硬化的进一步恶化。现综述特利加压素在肝硬化腹水相关并发症治疗中的药理基础、临床证据与应用特点,分析尚存在的问题并提出展望。
Ascites is the most common clinical symptom in the decompensated stage of patients with liver cirrhosis,and its co-existence in complex conditions,such as refractory ascites,hyponatremia,hepatorenal syndrome and other complications may harm seriously.Splanchnic vasodilation is the key pathological link of cirrhotic ascites-related complications and the treatment of this link can help to eliminate the symptoms of ascites and prevent the further deterioration of decompensated cirrhosis.This paper summaries the pharmacological basis,clinical evidence and application characteristics of a vasocative drugs-terlipressin in the treatment of cirrhotic ascites-related complications,and further analyzes the problems existing in the current research,then proposes a prospect.
作者
刘成海
邢枫
王静
Liu Chenghai;Xing Feng;Wang Jing(Institute of Liver Diseases,Shuguang Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2019年第12期929-932,共4页
Chinese Journal of Hepatology
关键词
肝硬化
腹水
并发症
特利加压素
内脏血管扩张
Liver cirrhosis
Ascites
Complication
Terlipressin
Splanchnic vasodilatation
